BTK inhibitor 10 is a potent and orally active Bruton kinase (BTK) inhibitor, extracted from patent WO2018145525, example 33. BTK inhibitor 10 has a potential for rheumatoid arthritis treatment.
性状
Solid
IC50 & Target[1][2]
IC50: Bruton kinase (BTK)
体内研究(In Vivo)
BTK inhibitor 10 (oral gavage; 30 mg/kg; 21 days; once daily) has a significant improvement in arthritis symptoms in CIA mice. The damage of each of the 4 paws in mice is divided into 0-4 to calculate the total score of the limbs. After 21 days’ oral treatment, BTK030 reduces the arthritic score to 3.62 while the control group shows a value of 8.33. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, sealed storage, away from moisture and light In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
参考文献
[1]. HuiJun Yin, et al. Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof. Patent WO2018145525
溶解度数据
In Vitro: DMSO : 50 mg/mL (113.26 mM; Need ultrasonic)配制储备液